Cartesian Therapeutics (RNAC) Return on Capital Employed (2016 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Return on Capital Employed of 53.54% for Q1 2026, down 4066.0% year-over-year from 1.35% in Q1 2025, and down 19.32% quarter-over-quarter from 44.87% in Q4 2025.
Cartesian Therapeutics (RNAC) Return on Capital Employed (2016 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Return on Capital Employed for 11 consecutive years, with 53.54% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 4066.0% year-over-year to 53.54%; the TTM figure through Mar 2026 stood at 53.54% (down 4066.0% YoY), while the FY2025 annual figure was 40.88%, down 2823.0% from the prior year.
- Return on Capital Employed fell to 53.54% in Q1 2026 per RNAC's latest filing, from 44.87% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.09% in Q2 2022 and bottomed at 62.92% in Q4 2023.
- Historically, Return on Capital Employed has averaged 20.02% across 5 years, with a median of 15.78% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 6396 bps — and 2023, when it tumbled 7397 bps.
- Cartesian Therapeutics' Return on Capital Employed stood at 9.89% in 2022, then plunged by 736 bps to 62.92% in 2023, then soared by 83 bps to 10.4% in 2024, then plunged by 332 bps to 44.87% in 2025, then slipped by 19 bps to 53.54% in 2026.
- Business Quant data shows RNAC's Return on Capital Employed at 53.54% in Q1 2026, 44.87% in Q4 2025, and 24.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | -54.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54.91% |
| Mar 31, 2026 | -53.54% |
| Dec 31, 2025 | -44.87% |
| Sep 30, 2025 | -24.93% |
| Jun 30, 2025 | -22.75% |
| Mar 31, 2025 | -12.88% |
| Dec 31, 2024 | -10.40% |
| Sep 30, 2024 | -14.07% |
| Jun 30, 2024 | -15.78% |
| Mar 31, 2024 | -29.22% |
| Dec 31, 2023 | -62.92% |
| Sep 30, 2023 | -56.97% |
| Jun 30, 2023 | -39.85% |
| Mar 31, 2023 | -10.89% |
| Dec 31, 2022 | 9.89% |
| Sep 30, 2022 | 17.00% |
| Jun 30, 2022 | 20.09% |
| Mar 31, 2022 | 11.74% |
| Dec 31, 2021 | -5.04% |
| Sep 30, 2021 | -21.19% |